IL2RA and neoplasm: Although earlier attempts to deplete intratumoral Treg cells with antibodies to CD25 were not successful60,61, a new CD25-directed antibody with enhanced binding to an activating Fc region allowed Treg cell-specific antibody-dependent cell-mediated cytotoxicity (ADCC) (Figure 2A), and when combined with a programmed death-1 (PD-1) blockade in mice, this treatment skewed the tumor-infiltrating lymphocyte (TIL) landscape towards activated, conventional T cells and improved rejection of established tumors59.